Literature DB >> 19144770

Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling.

Mohamad Shebley1, Ute M Kent, David P Ballou, Paul F Hollenberg.   

Abstract

Phencyclidine (PCP) is a mechanism-based inactivator of cytochrome P450 (P450) 2B6. We have analyzed several steps in the P450 catalytic cycle to determine the mechanism of inactivation of P450 2B6 by PCP. Spectral binding studies show that binding of benzphetamine, a type I ligand, to P450 2B6 was significantly affected as a result of the inactivation, whereas binding of the inhibitor n-octylamine, a type II ligand, was not compromised. Binding of these ligands to P450 2B6 occurs in two phases. Stopped-flow spectral analysis of the binding kinetics of benzphetamine to PCP-inactivated 2B6 revealed a 15-fold decrease in the rate of binding during the second phase of the kinetics (k(1) = 5.0 s(-1), A(1) = 30%; k(2) = 0.02 s(-1), A(2) = 70%, where A(2) indicates the fractional magnitude of the second phase) compared with the native enzyme (k(1) = 8.0 s(-1), A(1) = 58%; k(2) = 0.3 s(-1), A(2) = 42%). Analysis of benzphetamine metabolism by the inactivated protein using liquid chromatography/electrospray ionization/mass spectrometry showed that the rates of formation of nor-benzphetamine and hydroxylated nor-benzphetamine were decreased by 75 and 69%, respectively, whereas the rates of formation for amphetamine, hydroxybenzphetamine, and methamphetamine showed slight but statistically insignificant decreases after the inactivation. The rate of reduction of P450 2B6 by NADPH and reductase was decreased by 6-fold as a result of the modification by PCP. In addition, the extent of uncoupling of NADPH oxidation from product formation, a process leading to futile production of H(2)O(2), increased significantly during the metabolism of ethylbenzene as a result of the inactivation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144770      PMCID: PMC2680542          DOI: 10.1124/dmd.108.024661

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver.

Authors:  I H Hanna; J R Reed; F P Guengerich; P F Hollenberg
Journal:  Arch Biochem Biophys       Date:  2000-04-01       Impact factor: 4.013

2.  Comparison of substrate metabolism by cytochromes P450 2B1, 2B4, and 2B6: relationship of heme spin state, catalysis, and the effects of cytochrome b5.

Authors:  James R Reed; Paul F Hollenberg
Journal:  J Inorg Biochem       Date:  2003-01-15       Impact factor: 4.155

Review 3.  Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.

Authors:  Paul F Hollenberg; Ute M Kent; Namandjé N Bumpus
Journal:  Chem Res Toxicol       Date:  2007-12-04       Impact factor: 3.739

4.  The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine.

Authors:  Monica I Jushchyshyn; Ute M Kent; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

5.  The measurement of difference spectra: application to the cytochromes of microsomes.

Authors:  R W Estabrook; J Werringloer
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

6.  Hydrogen peroxide in hepatic microsomes.

Authors:  A G Hildebrandt; I Roots; M Tjoe; G Heinemeyer
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

7.  Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP).

Authors:  Craig Sams; George D Loizou; John Cocker; Martin S Lennard
Journal:  Toxicol Lett       Date:  2004-03-07       Impact factor: 4.372

8.  Mechanistic studies with N-benzyl-1-aminobenzotriazole-inactivated CYP2B1: differential effects on the metabolism of 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone, and benzphetamine.

Authors:  Ute M Kent; Lise Pascual; Rebecca A Roof; David P Ballou; Paul F Hollenberg
Journal:  Arch Biochem Biophys       Date:  2004-03-15       Impact factor: 4.013

9.  On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction.

Authors:  L D Gorsky; D R Koop; M J Coon
Journal:  J Biol Chem       Date:  1984-06-10       Impact factor: 5.157

10.  On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol.

Authors:  J R Halpert; N E Miller; L D Gorsky
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

View more
  4 in total

1.  Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity.

Authors:  Sean C Gay; Haoming Zhang; P Ross Wilderman; Arthur G Roberts; Tong Liu; Sheng Li; Hsia-Lien Lin; Qinghai Zhang; Virgil L Woods; C David Stout; Paul F Hollenberg; James R Halpert
Journal:  Biochemistry       Date:  2011-05-13       Impact factor: 3.162

2.  Small molecule quantification by liquid chromatography-mass spectrometry for metabolites of drugs and drug candidates.

Authors:  Upendra P Dahal; Jeffrey P Jones; John A Davis; Dan A Rock
Journal:  Drug Metab Dispos       Date:  2011-09-21       Impact factor: 3.922

3.  A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data.

Authors:  Ken Korzekwa; Donald Tweedie; Upendra A Argikar; Andrea Whitcher-Johnstone; Leslie Bell; Shari Bickford; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2014-06-17       Impact factor: 3.922

4.  Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?

Authors:  Judy L Bolton
Journal:  Curr Org Chem       Date:  2014-01-01       Impact factor: 2.180

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.